reports
- Vincent Koppmair
Shurgard - 76.9% approval of Lokn'Store takeover
Lok'nStore shareholders approve SHUR's bid by 76.9%.The acquisition stands at a yield of 8% (at maturity) and will allow SHUR to double in size in the UK. It is expected to be EPS accretive starting 2026.The acquisition is expected to be financed by a mix of debt and equity.We reiterated our ‘Buy' rating and EUR 47.00 TP. We will review our estimates in the coming weeks to include the acquisition.More details in our Note published this morning
Oxurion Receives Transparency Notification from Atlas Special Opportun...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – June 7, 2024 – 07:00 PM CET - (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on June 7, 2024, from Atlas Special Opportunities, LLC indicating that as of June 7, 2024, it held 1,785,024,954 shares of the then ou...
Roularta Media Group Nv: 1 director
A director at Roularta Media Group Nv bought 8,772 shares at 11.400EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
- ING Helpdesk
- Wim Hoste
- Kris Kippers
Oxurion Announces Extraordinary General Shareholders’ Meeting
Oxurion Announces Extraordinary General Shareholders’ Meeting Oxurion Announces Extraordinary General Shareholders’ Meeting Leuven, BELGIUM – June 4, 2024 – 07:00 PM CET – (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces an extraordinary general shareholders’ meeting to be held on Thursday July 4, 2024 at 11:00 AM (CET). This extraordinary general shareholders’ meeting regards the proposal of share consolidation in respect of all outstanding shares of the Company by means of a 1-for-10,000 share consolidation. The convening notice and other docu...
Oxurion Receives Transparency Notification from Atlas Special Opportun...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – May 27, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on May 24, 2024, from Atlas Special Opportunities, LLC indicating that as of May 22, 2024, it held 2,377,763,043 shares of the then outst...
Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 Ma...
Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 Leuven, BELGIUM – 23 May, 2024 – 07.00 PM CET – (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held its annual shareholders’ meeting on May 16, 2024. The shareholders approved all items on the agenda of the annual shareholders’ meeting. All documents pertaining to the annual shareholders' meeting held on May 16, 2024, can be consulted on Oxurion’s website . About Oxurion Oxurion (Euronext Brussels: O...
Information on the Total Number of Voting Rights (Denominator) followi...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven, ...
- Vincent Koppmair
Home Invest Belgium - Q1 2024 - Stellar start to the year
EPRA results is up 12% YoY due to higher rental income and improved operating margin, EPS up 1.5% from the dilution impact of 2023's ABB.LTV down ca. 300bps to 47% due to disposals (EUR 40m) and positive revaluation (+6.7% / EUR +50m).We raise our TP to EUR 20.50 (from EUR 18.00) and upgrade HOMI to ‘Buy' (from ‘Hold'). Our TP implies a 17% upside potential.More details in our Note published this morning
- ING Helpdesk
Benelux Morning Notes
Ahold Delhaize: Walmart 1Q24/25 results. Azelis: Share placement by EQT and PSP. Belgian telcos: Digi mobile prices to be well below competition, targets 10% mkt share. EVS: Slow start, sales guidance held on strong pipeline, EBIT guidance below consensus. Exmar: Stable start to the year. Prosus: Fabricio Bloisi (CEO iFood) appointed as group CEO. Sif Group: 1Q24 pretty much in line, timing shifts a bit
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Sharad Kumar S.P
- Wim Lewi
- Vincent Koppmair
Immobel - Not out of the woods yet
We reviewed our Immobel figures, following a market update for 2024 and adjusted our estimates.2024 is expected to be much better (sales +50%) yet still subdued (ROE remaining at mid single digits).Slow market reopening could imply a tough 2025 due to a delayed investment market reopening, the liquidity impact of the Proximus towers acquisition at the end of 2024 and a sizeable refinancing wall coming up.While revenues are expected to grow, we continue to see short-term pressure on the balance ...
Oxurion Receives Transparency Notification from Atlas Special Opportun...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – May 16, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on May 16, 2024, from Atlas Special Opportunities, LLC indicating that as of May 13, 2024, it held 1,000,850,000 shares of the th...
Deceuninck NV: 1 director
A director at Deceuninck NV sold 500,000 shares at 2.500EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Information on the Total Number of Voting Rights (Denominator) followi...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven, ...
Oxurion Receives Transparency Notification from Atlas Special Opportun...
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – May 13, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on May 9, 2024, from Atlas Special Opportunities, LLC indicating that as of May 2, 2024, it held 1,467,712,295 shares of the then outstan...
Important Advances in Oxurion's R&D Program on Geographic Atrophy seco...
Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD ` Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD Leuven, BELGIUM – May 6, 2024 – 6:00 PM CET, Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, today announces important progress in its preclinical program targeting Geographic Atrophy (GA), a severe and underserved form of Age-Related Macular Degeneration (AMD). This recently launched program has reached the first step with the identification of 50 targets that have the potent...
- Vincent Koppmair
Shurgard - Q1 2024 - A start to 2024
All store revenue up 7.1% YoY at EUR 93.4m driven by higher rent prices (4.2%), and larger portfolio (+4.9%), offset by lower occupancy (86.7%)Same store revenue up 4.0% (CER), average occupancy is down 60bps at 89.2% YoY, and in place rent up 3.3%.EPRA results up 12.6% YoY, EPRA EPS at EUR 0.35 (+3.1%) post ABB.Leverage remains very low at 14.6% (vs. 13% at December end) and net debt/EBITDA at 3.5x and ICR stands at 13.4x.We reiterate our ‘Buy' rating and EUR 47.00 TP.More details in our N...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.